Teva Pharmaceutical (TEVA) is still under-owned among long-term investors, but the stock has performed stronger and is positioned to do even better in 2025, UBS said in a note emailed Wednesday.
"We see Teva and parts of our [Specialty Pharmaceuticals] as relatively insulated from 2025 macro concerns around regulatory landscape shift/ macro policy concerns," UBS analysts led by Ashwani Verma wrote in the note.
UBS analysts highlighted that the company's recent strong phase 2 data from duvakitug study to treat inflammatory bowel disease, which exceeded investor expectations, strengthens its outlook.
Additionally, UBS analysts believe Teva's potential sale of active pharmaceutical ingredients business, expected to be announced in coming months, could "surprise to the upside."
UBS raised its price target on Teva to $28 from $26, and maintained its buy rating.
Teva shares were up more than 4% in recent trading.
Price: 21.80, Change: +0.92, Percent Change: +4.41
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。